<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01060306</url>
  </required_header>
  <id_info>
    <org_study_id>SMG-005</org_study_id>
    <nct_id>NCT01060306</nct_id>
  </id_info>
  <brief_title>Optical Coherence Tomography Evaluation of a Biodegradable Polymer-based Drug-eluting Stent</brief_title>
  <acronym>PONTINA</acronym>
  <official_title>Prospective Optical cohereNce Tomography Evaluation of neoINtimal Coverage of a biodegrAdable Polymer-based Drug-eluting Stent</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ospedale Santa Maria Goretti</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ospedale Santa Maria Goretti</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      PONTINA aims at assessing by optical coherence tomography the neointimal coverage of the
      biodegradable polymer-based Biolimus A9-eluting stent (Biomatrix stent) after full drug
      elution and polymer biodegradation (6 months), at one month after this time-point (7 months)
      and, as a comparator, of its bare metal stent counterpart (Gazelle stent) at 1 month after
      implantation.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Funding issues
  </why_stopped>
  <start_date type="Anticipated">January 2010</start_date>
  <completion_date type="Anticipated">January 2011</completion_date>
  <primary_completion_date type="Anticipated">August 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of neointimal coverage of the biodegradable polymer-based Biolimus A9-eluting stent (Biomatrix stent) after full drug elution and polymer biodegradation</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of neointimal coverage of the biodegradable polymer-based Biolimus A9-eluting stent (Biomatrix stent) one month after full drug elution and polymer biodegradation</measure>
    <time_frame>7 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of neointimal coverage of the biodegradable polymer-based Biolimus A9-eluting stent (Biomatrix stent) one month after full drug elution and polymer biodegradation and of its bare metal stent counterpart (Gazelle) one month after implantation</measure>
    <time_frame>7 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of the neointimal coverage of the biodegradable polymer-based Biolimus A9-eluting stent (Biomatrix stent) after full drug elution and polymer biodegradation (6 months) and at one month after this time-point (7 months)</measure>
    <time_frame>7 months</time_frame>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">0</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Bare metal stent 1 month</arm_group_label>
    <description>Patients implanted with the bare metal stent Gazelle evaluated for neointimal coverage one month after implantation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Biodegradable polymer stent 6 months</arm_group_label>
    <description>Patients implanted with the biodegradable polymer-based Biolimus A9-eluting stent (Biomatrix stent) evaluated for neointimal coverage after full drug elution and polymer biodegradation (6 months)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Biodegradable polymer stent 7 months</arm_group_label>
    <description>Patients implanted with the biodegradable polymer-based Biolimus A9-eluting stent (Biomatrix stent) evaluated for neointimal coverage one month after full drug elution and polymer biodegradation (7 months)</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with stable or unstable coronary artery disease undergoing percutaneous coronary
        intervention on the left anterior descending artery with a Biomatrix stent placement or on
        the left circumflex artery with a Gazelle stent placement
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age &gt;50 years

          -  de novo lesion

          -  lesion length &lt;24 mm

          -  reference vessel diameter 3 mm

        Exclusion Criteria:

          -  low compliance to dual antiplatelet therapy

          -  life expectancy &lt;1 year

          -  allergy to any drug or substance use prior, during or after percutaneous coronary
             intervention

          -  chronic renal insufficiency

          -  low left ventricle ejection fraction (&lt;35%)

          -  recent acute myocardial infarction

          -  previous coronary intervention

          -  off-label indication to stenting

          -  participation in another investigation

          -  refusal to participate to the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>UOC Emodinamica e Cardiologia Interventistica - Ospedale Santa Maria Goretti</name>
      <address>
        <city>Latina</city>
        <zip>04100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 1, 2010</study_first_submitted>
  <study_first_submitted_qc>February 1, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 2, 2010</study_first_posted>
  <last_update_submitted>February 21, 2020</last_update_submitted>
  <last_update_submitted_qc>February 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ospedale Santa Maria Goretti</investigator_affiliation>
    <investigator_full_name>Gregory Sgueglia, MD</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

